What is DaShenLin Pharmaceutical Group Co., Ltd.'s (603233.SS) StockRank?

MoatMap's StockRank for DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is 98/100, with a Strong Buy signal. This is a composite score combining Quality (71), Value (76), and Momentum (64) factor ranks across MoatMap's universe of 25,000+ stocks.

Does DaShenLin Pharmaceutical Group Co., Ltd. have an economic moat?

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is DaShenLin Pharmaceutical Group Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is DaShenLin Pharmaceutical Group Co., Ltd. in?

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) operates in the Healthcare sector, specifically the Pharmaceutical Retailers industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603233.SS

Strong BuyFull HouseAPPROVE

DaShenLin Pharmaceutical Group Co., Ltd. · Healthcare · China · $3.1B · Avg Vol: $23M/d

StockRank

Get insider-trade alerts

P/E (TTM)

15.5x

ROE

17.0%

D/E

0.6x

Dividend %

4.5%

AI CONVICTION THESIS

Meets eligibility criteria across all legs and possesses a positive forward-EPS consensus revision, confirming operational momentum. As a dominant pharmacy player, it fits the high-moat compounder thematic.

COMPANY DESCRIPTION

DaShenLin Pharmaceutical Group Co., Ltd. is one of China's largest retail pharmacy chains, operating thousands of drugstores primarily in southern and western China. The company offers prescription and OTC drugs, traditional Chinese medicine, and healthcare products, leveraging a highly standardized store-operating model. Its competitive moat is built on massive purchasing scale, strong regional brand dominance, and an expanding digital healthcare and online-to-offline (O2O) service platform.

FINANCIAL SUMMARY (CNY)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	21.2B	24.5B	26.5B	27.5B	9.0%	28.0B	29.5B	32.5B	8.7%
EPS (CNY)	0.91	1.03	0.81	1.08	5.9%	1.21	1.32	1.54	19.4%
Shares	1.1B	1.1B	1.1B	1.1B	-0.0%	1.1B	—	—	—
Debt	5.9B	6.5B	7.5B	5.5B	-2.5%	5.3B	—	—	—
Equity	6.2B	6.8B	6.9B	7.4B	5.9%	—	—	—	—
Op CF	3.8B	3.2B	3.1B	5.4B	12.5%	3.7B	—	—	—
Inv CF	-1.3B	-2.3B	-1.9B	-970.3M	—	—	—	—	—
Fin CF	-933.6M	-1.6B	-931.9M	-3.7B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-1.9%

SMA 50SMA 200

$2.72

RSI (14)

48.1

52W High

$3.15

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

16.9%86.7

ROE

17.0%85.4

GP/Assets

37.0%74.3

Op. Margin

9.4%60.9

FCF/Assets

12.6%90.8

Piotroski

783.9

Int. Cover

24.9x73.0

D/E Ratio

0.59x25.4

Current Ratio

0.90x8.9

Value

P/E (TTM)

15.5x72.5

EV/EBITDA

8.8x75.2

P/FCF

6.3x90.9

P/B

2.8x48.7

P/S

0.8x88.3

Div Yield

4.5%86.6

Momentum

52W High %

86%79.8

RS 6M

3%68.1

SMA 50/200

1.04x65.1

EPS Rev 4W

+0.7%46.5

EPS Rev 12W

+10.0%85.8

EPS Improve

+26%38.3

Q Growth

23%57.8

FUNDAMENTALS

Market Cap

$3.1B

P/E (Forward)

12.4x

Gross Margin

34.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603233.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603233.SS	DaShenLin Pharmaceutical Group Co., Ltd.(you)	$3.1B	98	Strong Buy
603939.SS	Yifeng Pharmacy Chain Co., Ltd.	$4.1B	94	Strong Buy
603883.SS	LBX Pharmacy Chain Joint Stock Company	$1.5B	89	Strong Buy
002727.SZ	Yixintang Pharmaceutical Group Co., Ltd.	$980M	86	Strong Buy
1345.HK	Shanghai Pioneer Holding Ltd	$331M	98	Strong Buy
6618.HK	JD Health International Inc.	$14.9B	83	Strong Buy
301408.SZ	Anhui Huaren Health Pharmaceutical Co., Ltd.	$886M	64	Hold
9885.HK	YSB Inc.	$316M	78	Buy
002788.SZ	Luyan Pharma Co.,Ltd.	$642M	53	Hold
301017.SZ	ShuYu Civilian Pharmacy Corp., Ltd.	$814M	44	Hold

Peer medians: ROE 4.4% · P/E 28.1x · Gross margin 53.2%

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS): Stock Score Summary

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) has a MoatMap StockRank of 98/100 based on Quality (71/100), Value (76/100), and Momentum (64/100) factor scores. The current signal is STRONG BUY. Meets eligibility criteria across all legs and possesses a positive forward-EPS consensus revision, confirming operational momentum. As a dominant pharmacy player, it fits the high-moat compounder thematic.

Key Financial Metrics

Price	$2.72
Market Cap	$3.1B
P/E (TTM)	15.53
P/E (Forward)	12.36
Price/Book	2.80
Return on Equity	17.0%
Return on Invested Capital	16.9%
Debt/Equity	0.59x
Gross Margin	34.6%
Operating Margin	9.4%
Revenue Growth	6.9%
Dividend Yield	4.5%
Free Cash Flow	$491M

DaShenLin Pharmaceutical Group Co., Ltd. operates in the Pharmaceutical Retailers industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is DaShenLin Pharmaceutical Group Co., Ltd.’s (603233.SS) StockRank?: MoatMap’s StockRank for DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is 98/100, with a Strong Buy signal. It is a composite of Quality (71), Value (76), and Momentum (64) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does DaShenLin Pharmaceutical Group Co., Ltd. have an economic moat?: DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is DaShenLin Pharmaceutical Group Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is DaShenLin Pharmaceutical Group Co., Ltd. in?: DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS) operates in the Healthcare sector, specifically the Pharmaceutical Retailers industry (China).